Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Resectable Head and Neck Squamous Cell Carcinoma: early-phase trial registry
4 of 4 indexed Resectable Head and Neck Squamous Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 4 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Resectable Head and Neck Squamous Cell Carcinoma: 4 US clinical trials tracked, 4 recruiting.
Resectable Head and Neck Squamous Cell Carcinoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 1 of these trials.
Enrollment posture brief
Registry condition resectable-head-and-neck-squamous-cell-carcinoma
OPEN 4 | RECR 100% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Resectable Head and Neck Squamous Cell Carcinoma lists 4 open slots (100% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Resectable Head and Neck Squamous Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Resectable Head and Neck Squamous Cell Carcinoma is recruiting above its size-band peers.
4 of 4 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
Ohio State University Comprehensive Cancer Center
NCT04754321
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
University of Michigan Rogel Cancer Center
NCT07094685
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Dana-Farber Cancer Institute
NCT05726370
Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer
Mayo Clinic
NCT06997094
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Resectable Head and Neck Squamous Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Resectable Head and Neck Squamous Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Resectable Head and Neck Squamous Cell Carcinoma page
4 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Resectable Head and Neck Squamous Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Resectable Head and Neck Squamous Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Resectable Head and Neck Squamous Cell Carcinoma condition card totals 4 registered trials; most-linked intervention External Beam Radiation Therapy; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.